Detalhe da pesquisa
1.
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.
Proc Natl Acad Sci U S A
; 120(3): e2207291120, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634138
2.
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
Mult Scler
; 28(13): 2027-2037, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35903888
3.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Mult Scler
; 28(10): 1576-1590, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229668
4.
Brain volume loss in individuals over time: Source of variance and limits of detectability.
Neuroimage
; 214: 116737, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171923
5.
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
Can J Neurol Sci
; 47(4): 437-455, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654681
6.
Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
J Immunol
; 198(2): 691-698, 2017 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27974457
7.
Virtual Management of Multiple Sclerosis: Providing Access or Just Phoning it in?
Can J Neurol Sci
; 51(1): 113-116, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37066757
8.
Health Canada drug approval process: a barrier to personalized care in multiple sclerosis.
Can J Neurol Sci
; : 1-12, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777804
9.
Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing.
Can J Neurol Sci
; 45(5): 489-503, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29893652
10.
Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.
Can J Neurol Sci
; 45(3): 304-312, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29756588
11.
Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned?
Can J Neurol Sci
; 49(3): 402-405, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33998416
12.
Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
J Immunol
; 202(7): 2172, 2019 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770414
13.
Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Can J Neurol Sci
; 43(1): 33-43, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26611431
14.
From progression to progress: The future of multiple sclerosis.
J Cent Nerv Syst Dis
; 16: 11795735241249693, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711957
15.
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
JAMA Neurol
; 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38466277
16.
Rebound disease in multiple sclerosis.
Mult Scler
; 24(8): 1137-1138, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29708464
17.
Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software.
Front Neurol
; 14: 1243594, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37745656
18.
Laquinimod in multiple sclerosis.
Clin Immunol
; 142(1): 38-43, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21450529
19.
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
N Engl J Med
; 370(5): 486-8, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24476450
20.
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.
Brain Sci
; 12(2)2022 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35203978